, /PRNewswire/ — BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812, , has been accepted by the China National Medical Products Administration (NMPA) (Acceptance No. CXSL2300366). LIV-1, also known as SLC39A6 or ZIP6,…Read More
BioRay Filed IND Application for BRY812 a Novel Antibody Drug Conjugate Targeting LIV1
